JCP

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER
[Advanced]

Published Online First: 3 August 2007. doi:10.1136/jcp.2007.049411
Journal of Clinical Pathology 2008;61:297-300
Copyright © 2008 by the BMJ Publishing Group Ltd & Association of Clinical Pathologists.

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
jcp.2007.049411v1
61/3/297    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this link to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Add article to my folders
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kaur, C
Right arrow Articles by Cook, M G
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kaur, C
Right arrow Articles by Cook, M G
Right arrowPubmed/NCBI databases
Medline Plus Health Information
*Melanoma
*Skin Cancer

ORIGINAL ARTICLES

The correlation of regression in primary melanoma with sentinel lymph node status

C Kaur1, R J Thomas1, N Desai2, M A Green1, D Lovell3, B W E M Powell4, M G Cook1,3

1 Department of Histopathology, Royal Surrey County Hospital, Guildford, UK
2 Department of Dermatology, St George’s Hospital, London, UK
3 Postgraduate Medical School, Guildford, UK
4 Department of Plastic Surgery, St George’s Hospital, London, UK

Correspondence to:
Professor M G Cook, Royal Surrey County Hospital, Egerton Road, Guildford GU2 7XX, UK; m.cook{at}nhs.net

Background: The significance of regression in primary melanoma has been disputed for many years. Some have suggested regression as a marker for poor prognosis while others have reported a negligible or even a favourable effect, on prognosis.

Aim: To understand the significance of regression in melanoma and provide further information on whether patients should be subjected to sentinel lymph node biopsy (SLNB) on the basis of regression.

Methods: 146 melanoma cases who had undergone SLNB were included in the study. The histological criteria for offering SLNB were melanoma >1 mm in thickness, Clark’s level IV or those with regression.

Results: A statistically significant greater proportion of individuals without regression showed sentinel lymph node (SLN) positivity (p = 0.028) compared with those which do show regression. Metastatic disease correlated with growth phase of the primary lesion. All the node positive cases were in the vertical growth phase; none of the cases in radial growth phase and showing regression were associated with nodal metastasis (p = 0.029). 62 cases had melanomas with thickness <1 mm and were in radial growth phase, yet were offered SLNB because of regression. Of these, 44 showed features of regression and all were node negative. The remaining 16 cases of thin melanomas did not show regression; 2 of these had sentinel node metastasis.

Conclusion: Results suggest that regression is usually a favourable process, particularly in thin melanomas and that metastasis in "thin melanomas showing regression" is real but rare. Variant vertical growth phase, mitoses and other prognostically significant variables may be more important predictors of metastatic potential in thin melanomas.





This article has been cited by other articles:


Home page
J. Clin. Pathol.Home page
M G Cook and S Di Palma
Pathology of sentinel lymph nodes for melanoma
J. Clin. Pathol., August 1, 2008; 61(8): 897 - 902.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER
Journal of Clinical Pathology Molecular Pathology
Terms and conditions relating to subscriptions purchased online  ¦  Website terms and conditions  ¦  Privacy policy
Copyright © 2008 by the BMJ Publishing Group Ltd & Association of Clinical Pathologists.